Universal reference book for medicines
Product name: OXACILLIN (OXACILLIN)

Active substance: oxacillin

Type: Penicillin-resistant penicillinase-resistant antibiotic

Manufacturer: SYNTHESIS (Russia)
Composition, form of production and packaging
Powder for solution for I / O and /
or injection white or almost white, hygroscopic.

1 f.

Oxacillin (in the form of the sodium salt) 1 g

Vials (1) - packs of cardboard.

Vials (5) - packs of cardboard.

Vials (10) - packs of cardboard.

Vials (50) - cardboard boxes.

Powder for solution for I / O and / or injection white or almost white, hygroscopic.

1 f.

Oxacillin (in the form of the sodium salt) 250 mg

Vials (1) - packs of cardboard.

Vials (5) - packs of cardboard.

Vials (10) - packs of cardboard.

Vials (50) - cardboard boxes.

Powder for solution for I / O and / or injection white or almost white, hygroscopic.

1 f.

Oxacillin (in the form of the sodium salt) 500 mg

Vials (1) - packs of cardboard.

Vials (5) - packs of cardboard.

Vials (10) - packs of cardboard.

Vials (50) - cardboard boxes.

Powder for the preparation of a solution for the / m introduction of white or almost white color, hygroscopic.

1 f.

Oxacillin (in the form of the sodium salt) 250 mg

Vials (1) - packs of cardboard.

Vials (5) - packs of cardboard.

Vials (10) - packs of cardboard.

Powder for the preparation of a solution for the / m introduction of white or almost white color, hygroscopic.

1 f.

Oxacillin (in the form of the sodium salt) 500 mg

Vials (1) - packs of cardboard.

Vials (5) - packs of cardboard.

Vials (10) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

The product description was approved by the manufacturer for the 2009 print edition.

PHARMACHOLOGIC EFFECT

Bactericidal antibiotic from the group of semisynthetic penicillins, is resistant to the action of penicillinase.
It blocks the synthesis of the bacterial cell wall by disrupting the late stages of peptidoglycan synthesis (prevents the formation of peptide bonds by inhibiting transpeptidase), causes lysis of fissile bacterial cells.
It is active against gram-positive microorganisms: Staphylococcus spp.
(including those producing penicillinase), Streptococcus spp., incl. Streptococcus pneumoniae, Corynebacterium diphtheriae, Bacillus anthracis, anaerobic spore-forming rods, Gram-negative cocci (Neisseria gonorrhoeae, Neisseria meningitidis), Actinomyces spp., Treponema spp.
It is inactive with respect to the majority of gram-negative bacteria, rickettsia, viruses, protozoa, fungi.
Sustainability develops slowly.
PHARMACOKINETICS

Absorption is fast and complete.
It is stable in slightly acidic medium. The connection with plasma proteins is about 90%. T 1/2 - 30 minutes. The time to reach C maxafter intravenous administration is 1-2 h, the concentration decreases rapidly to 4 h. With parenteral administration, higher concentrations are achieved in the blood than when taken by mouth. In the pleural fluid is found in a concentration reaching 10%, synovial and ascitic fluid - 50%, bile - 5-8% in relation to its concentration in the blood serum. Does not penetrate intact GEB, with inflammation of the meninges the penetration increases. Penetrates through the placental barrier, is found in breast milk. More than 40% after the / m introduction quickly excreted by the kidneys, with bile - 10%.
INDICATIONS

Infectious diseases caused by gram-positive microorganisms that produce and do not produce penicillinase:

- sepsis;

- abscess;

- phlegmon;

- cholecystitis;

- Pielit;

- Cystitis;

- osteomyelitis;

- postoperative, wound infections, infected burns;

- bacterial endocarditis;

- meningitis;

- Sinusitis.

DOSING MODE

Adults and children over 6 years of age - 2-4 g / day.

Children under the age of 3 months - 60-80 mg / kg / day, from 3 months to 2 years - 1 g / day, from 2 to 6 years - 2 g / day.

Newborn and premature children - 20-40 mg / kg / day.

Multiplicity of administration - 4 times / day (every 4-6 hours).
The duration of treatment is usually 7-10 days. In severe forms of the disease (sepsis, septic endocarditis) treatment can last for 2-3 weeks or more.
When preparing solutions for intravenous injections , a bottle of 250 mg is added with 1.5 ml, with 500 mg - 3 ml of water for injection.

When preparing solutions for intravenous administration , 250 mg or 500 mg is dissolved in 5 ml of water for injection or 0.9% solution of sodium chloride and injected slowly, for 5-10 minutes.

For iv injection of oxacillin sodium salt is dissolved in 0.9% solution of sodium chloride or in a 5% solution of dextrose to a concentration of 0.5-2 mg / ml and injected for 1-2 hours at a speed of 60-100 drops / min.

SIDE EFFECT

Allergic reactions: skin itching, urticaria, less often angioneuroticeski edema, bronchospasm, in rare cases anaphylactic shock, eosinophilia.

From the digestive system: dyspepsia (nausea, vomiting, diarrhea);
pseudomembranous enterocolitis, candidiasis of the oral cavity; hepatotoxic effect - often develops at a dose of 6 g / day (hyperthermia, nausea, vomiting, icterus sclera or skin, increased activity of hepatic transaminases).
From the genitourinary system: hematuria, proteinuria, interstitial nephritis, vaginal candidiasis.

CONTRAINDICATIONS

- Hypersensitivity, incl.
to other beta-lactam antibiotics.
With caution: a history of allergic reactions and / or bronchial asthma, chronic renal failure (CRF), enterocolitis on the background of antibiotics (in the anamnesis).

PREGNANCY AND LACTATION

At pregnancy and in a lactemia appoint only on vital indications.
The use of the drug during pregnancy and during lactation is possible only if the intended benefit for the mother exceeds the potential risk to the fetus.
Oxacillin is excreted in breast milk, therefore, if it is necessary to prescribe the drug during lactation, breastfeeding should be stopped.

APPLICATION FOR FUNCTIONS OF THE LIVER

With caution: chronic renal failure.

APPLICATION FOR CHILDREN

Children over 6 years - 2-4 g / day.

Children under the age of 3 months - 60-80 mg / kg / day, from 3 months to 2 years - 1 g / day, from 2 to 6 years - 2 g / day.

Newborn and premature children - 20-40 mg / kg / day.

SPECIAL INSTRUCTIONS

It is inappropriate to use in infections caused by microorganisms that are sensitive to benzylpenicillin.

DRUG INTERACTION

Increases the toxicity of methotrexate (competition for tubular secretion).

It may be necessary to increase the doses of calcium folinate (antidote for antagonists of folic acid) and its longer use.

The combination of ampicillin or benzylpenicillin with oxacillin is rational, since the latter, suppressing the activity of penicillinase, reduces thereby the destruction of ampicillin and benzylpenicillin.
The spectrum of action with this combination becomes wider.
It is necessary to avoid joint use with other drugs that have a hepatotoxic effect.

It is not recommended to prescribe concomitantly with bacteriostatic antibiotics (decreased efficacy).

Drugs that block tubular secretion, increase the concentration of oxacillin in the blood.

Antacids and laxatives reduce the absorption of the drug from the digestive tract.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

List B. Keep out of reach of children, dry place at a temperature of no higher than 25 В° C.
Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!